longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Cormedix

CRMD

7.7200.90% ( -0.070 )
Closed: Sep 18, 16:00:00 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 3.23, below the reasonable range, cheaper than 89.23% of the time in the past 1 years, and the industry ranks 5/257, the industry Median -1.31.

3.23xP/E
$7.72Stock price
$2.39Earnings per share
3.23xP/E
Stock price$7.72Earnings per share$2.39

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
3.63x
Typical range
3.39x–5.57x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
SGIOYUSShionogi
9.42x--$15.86B
HYPMYUSHypera S.A.
9.66x--$3.17B
INVAUSInnoviva
4.28x34.79%$1.53B
APMDUSApnimed
7.06x114.94%$1.15B
CRMDUSCormedix
3.23x76.08%$601.73M
ORMPUSOramed Pharma
1.13x198.00%$197.17M
OGIUSOrganigram
2.28x511.47%$141.75M
SDEVUSStablecoin Development
0.11x--$52.64M
BTMDUSbiote Corp.
8.34x127.70%$48.86M
OWPCUSOne World Products, Inc.
0.04x--$142.42K

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.